New York: The US researchers have developed mini human lungs in lab dishes using adult stem cells featuring all types of cells that make up the human organ for testing of new treatments for respiratory diseases, including Covid-19.
The first adult human "lung-in-a-dish" models, described in the journal eLife, are also known as lung organoids and represent all cell types.
The SARS-CoV-2 infection of the lung organoids replicates real-world patient lung infections and reveals the specialised roles various cell types play in infected lungs, said the team at the University of California-San Diego.
"This human disease model will now allow us to test drug efficacy and toxicity, and reject ineffective compounds early in the process, at 'Phase 0', before human clinical trials begin," said Pradipta Ghosh, Professor, at UC San Diego School of Medicine.
The stem cell scientists reproducibly developed three lung organoid lines from adult stem cells derived from human lungs that had been surgically removed due to lung cancer. With a special cocktail of growth factors, they were able to maintain cells that makeup both the upper and lower airways of human lungs, including specialized alveolar cells known as AT2.
By infecting the lung organoids with SARS-CoV-2, the team discovered that the upper airway cells are critical for the virus to establish infection, while the lower airway cells are important for the immune response. Both cell types contribute to the overzealous immune response, sometimes called a cytokine storm that has been observed in severe cases of Covid-19.
A computational team validated the new lung organoids by comparing their gene expression patterns -- which genes are "on" or "off" -- to patterns reported in the lungs of patients who succumbed to the disease, and to those that they previously uncovered from databases of viral pandemic patient data.
Whether infected or not with SARS-CoV-2, the lung organoids behaved similarly to real-world lungs. In head-to-head comparisons using the same yardstick (gene expression patterns), the researchers showed that their adult lung organoids replicated Covid-19 better than any other current lab model.
Other models, for example, foetal lung-derived organoids and models that rely only on upper airway cells, allowed robust viral infection but failed to mount an immune response.
"Our lung organoids are now ready to use to explore the uncharted territory of Covid-19, including post-Covid complications, such as lung fibrosis," said Soumita Das, PhD, associate professor of pathology at UC San Diego.
"We have already begun to test drugs for their ability to control viral infection -- from entry to replication to spread -- the runaway immune response that is so often fatal, and lung fibrosis," she added.